Dasatinib

Target: This ligand targets BCR-ABL/ABL1 and Src-family tyrosine kinases in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for BCR-ABL/ABL1 and Src-family tyrosine kinases. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings BCR-ABL/ABL1 into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• Dasatinib as Kinase Binder: Dasatinib can be used as a PROTAC-recruiting ligand to engage specific tyrosine kinases and drive ubiquitin-dependent degradation. By conjugating Dasatinib to an E3 ligase-recruiting moiety, researchers can convert kinase inhibition into targeted protein removal, enabling studies of degradation-driven signaling rewiring and pathway dependence.

• Targeted Degradation of BCR-ABL: Dasatinib’s strong affinity for BCR-ABL makes it a valuable starting point for PROTAC designs aimed at degrading this oncogenic kinase. PROTAC-mediated degradation can be leveraged to compare loss-of-function phenotypes versus catalytic inhibition, including assessment of downstream phosphorylation, survival signaling, and resistance mechanisms linked to kinase turnover.

• Optimize Degrader Potency: Dasatinib-based PROTACs support systematic structure–activity optimization, including linker length, attachment site selection, and E3 ligase choice. These parameters influence ternary complex formation, ubiquitination efficiency, and residence time, allowing researchers to tune degradation potency and selectivity while minimizing off-target degradation.

• Study Resistance via Turnover: Dasatinib-derived PROTACs can be used to investigate how altered kinase dynamics affect resistance. By degrading rather than inhibiting, these constructs help dissect whether resistance phenotypes arise from reduced binding, impaired ubiquitination, or compensatory pathway activation, using quantitative proteomics and time-resolved degradation kinetics.

• Map Signaling Dependencies: Employing Dasatinib in PROTAC research enables mapping of signaling dependencies on kinase protein abundance. Degradation titration experiments can reveal whether cellular responses correlate with protein depletion levels, identify feedback loops, and distinguish degradation-sensitive versus inhibition-only effects across kinase-driven networks.

Dasatinib is an ABL/Src-family kinase ligand scaffold suitable for kinase-directed PROTAC design. Its hydroxyethylpiperazine region provides a plausible vector for linker modification.

Structure: Dasatinib is a kinase ligand containing a thiazole carboxamide, aminopyrimidine core, chloromethylphenyl substituent, and hydroxyethylpiperazine side chain. The scaffold combines heteroaryl hinge-binding functionality with a basic and polar side chain.

Reactivity: Dasatinib-derived PROTAC design should preserve the thiazole-aminopyrimidine kinase-binding pharmacophore. Linker installation is most plausibly directed through the hydroxyethylpiperazine side chain or another solvent-exposed piperazine vector. Alkyl, PEG, ether, amide, carbamate, or tertiary-amine-compatible linkers may be connected to CRBN, VHL, or IAP ligands, with binding validation required for ABL/Src-family target engagement.